on my right, we have ted mitchell, the under secretary of the u.s. department of education. he has served since his confirmation earlier this year. in this role, he oversees policy programs and activities related to post secondary education, career and technical education, adult and federal student aid. ted is charged with planning and policy to have the u.s. have the most competitive work force in the world by the year 2020. next we have david baime who serves as senior vice president for government relations and policy analysis at the american association of community colleges. in this role he directs the efforts for the nation's close to 1,200 community colleges and their students. we're happy to have david here today to speak about the association's strategic plan to boost as much as 50% the number of degrees and credentials awarded at institutions by 2020. next we have sarah audelo. sarah's work focuses on ensuring that the next generation of americans have access to an affordable and high quality education. she will discuss how these policy proposals have the potential

ted bailey with john's infectiousision of disease. a question for mitchell warren and margaret, as well. dr. fauci pointed out he mapped the scientific pathway and i wanted to build on the analogy polio and ask a little bit about the legal pathway and pathway for carrying that through and the issue i have -- jonas salk's quote that he'd rather patent the sun. we had in the early 1990's, even though we're in a post-do had a world, we're seeing significant barriers. i'm wondering about the terms of the predevelopment partnerships, terms oftions and those so we can ensure that the price of the falcons is such uptake isn't limited and we tolize the promise inherent these vaccines. >> i'll is that right that since a critical issue for us. we consider iavi a public good funded by governments, flynn mists, et cetera and consider is mission that a vaccine developed for those who need it the most so what you ask is central to the work we need to have intellectual property on any discoveries dore involved in and we also get involved in licensing technology to biotech

. >> doctor ted the daily with johns hopkins. a couple for mitchell warren and margaret as well. dr. fauci pointed out he mapped the scientific method i want to maybe build on that, the analogy to call them and ask about the legal pathway, a policy pathway for curing that. the issue i have goes back to jonas salk's quote about he would sooner patent his son. incubus on the difficulty we have in the late 90s with intellectual property seems fitting to the doha round and living to -- even though we're in a doha world with hepatitis c can we're seeing significant barriers to access to new drug acting at the prospect am wondering about the terms of these predevelopment partnerships that you talk about. the conditions and terms of those so that we can ensure the price of the vexing such that update actually isn't limited we do in fact realize the promise inherent to these vaccines. >> yes. i'll start on that since it's a very critical issue for us. we consider, funded by governments, platypus, et cetera, and we also consider our mission to ensure that a vaccine is developed for those

ted bailey with johns happen kins division -- hopkins division of infectious diseases. question for mitchell and margaret you, point out he match the scientific path way and i which either individually or together start to result in a pretty high level of preventive benefits. how do you find 50% or 60% effective vaccine? does it get hidden behind these interventions? >> i would love to see the search for a silver bullet or magic bullet stopped. if we are searching for a silver bullet we should focus on something else. i don't think there will be one. that's not a defeatist attitude it's a realistic attitude. i don't get to decide levels of efficacy the regulators do but we do know the 31% efficacy, regulators in thailand where the trial took place were clear that wasn't good enough. the number often bandied about is 50% but every regulatory agency would make a decision based on risk and benefit but we use that some what as the lowest level and i think this issue of combination plays out in two ways. the future clinical trials will be complicated, we hope are complicated by the fact that this

the panel includes education under secretary ted mitchell and college administrators. this is just over an hour. >>> good morning. welcome to the center for american progress. i'm happy to see so many people here this early on a monday morning after a delightful fall weekend in our nation's capital. we are here today to release a report, issue brief, an interactive website that highlights findings of the significant body of work done over the last several months by the post secondary education team here at the center for american progress. we call that body of work a great recession, a great retreat. public investment in higher education is vital to the performance of our economy. colleges, universities, offer citizens a path toward economic opportunity. and a substantial return on public investment. force is needed for an economic experience through sustained employment, higher earnings, new and continued business development and ultimately higher tax revenues. but there are troubling signs. after the great recession, states have withdrawn public investment in higher

ted bailey with the division of infectious diseases. question for mitchell and margaret you, point out he match the scientific path way and i want to build on the analogy to polio and ask a little bit about the legal pathway and policy pathway for curing that. the issue goes back to the quote about the sun and thinking about the difficulties in the late 90s with intellectual property seen as a barrier leading to flexibilities. even though we have hepatitis c. i am wondering about these redevelopment partnerships. the conditions that the price of the vaccine is such that uptick actually isn't limited and we realized the problems inherent in vaccines. >> a very critical issue for us. we consider iavi a public good funded by government, philanthropists and so on and we consider our mission to ensure a vaccine is developed by those who needed the most. what we ask is central to the work we need to do so we have intellectual property on any discoveries that we are involved in and we also get involved in licensing technology to fund our biotech companies the with